1. Home
  2. SOS vs BIVI Comparison

SOS vs BIVI Comparison

Compare SOS & BIVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SOS Limited

SOS

SOS Limited

N/A

Current Price

$0.20

Market Cap

14.9M

Sector

Finance

ML Signal

N/A

Logo BioVie Inc.

BIVI

BioVie Inc.

N/A

Current Price

$1.34

Market Cap

12.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SOS
BIVI
Founded
2004
2013
Country
China
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
14.9M
12.4M
IPO Year
2005
2013

Fundamental Metrics

Financial Performance
Metric
SOS
BIVI
Price
$0.20
$1.34
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
★ $5.26
AVG Volume (30 Days)
213.5K
★ 839.8K
Earning Date
10-07-2026
11-17-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 74.83
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.19
$0.82
52 Week High
$2.08
$3.79

Technical Indicators

Market Signals
Indicator
SOS
BIVI
Relative Strength Index (RSI) 33.02 47.50
Support Level N/A $1.15
Resistance Level $0.24 $1.42
Average True Range (ATR) 0.02 0.22
MACD 0.01 0.01
Stochastic Oscillator 22.22 14.48

Price Performance

Historical Comparison
SOS
BIVI

About SOS SOS Limited

SOS Ltd is a multifaceted company that leverages the power of data to provide marketing solutions, while also participating in the burgeoning fields of blockchain and cryptocurrency operations, as well as commodity trading. Its product offerings are diversified across four main areas: commodity trading, insurance marketing and other Hosting services. The company has single reporting segment: Commodity trading and generates key revenue is generated from Commodity trading.

About BIVI BioVie Inc.

BioVie Inc is a clinical-stage company developing drug therapies for the treatment of neurological and neurodegenerative disorders and liver disease. Its therapeutic areas include Alzheimer's, Parkinson's, Long COVID, Ascites, Longevity, and Epigenetics. In liver disease, its investigational drug candidate BIV201 (continuous infusion terlipressin) was granted FDA Fast Track status and FDA Orphan Drug designation for ascites due to all etiologies except cancer. BIV201 is being evaluated as a treatment option for patients suffering from life-threatening complications of liver cirrhosis and ascites due to hepatitis, nonalcoholic steatohepatitis, and alcoholism.

Share on Social Networks: